Febrile neutropenia. Other diseases of blood and blood-forming organs
Conditions
Interventions
Intervention 1: Intervention group: In this group, meropenem is administered as an extended infusion over 3 hours at a dose of 20 mg/kg every 8 hours. Intervention 2: Control group: In this group, mer
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: Children Under 18 Years of Age with Cancer and Febrile Neutropenia Receiving Meropenem for at Least 48 Hours
Exclusion criteria
Exclusion criteria: Hypersensitivity to Meropenem Early death (before 48 hours) Undergoing bone marrow transplantation during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality rate. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Length of hospital stay. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Treatment success or failure. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Serum meropenem levels. Timepoint: 4 hours after receiving the third dose of meropenem and immediately before administration of the fourth dose of meropenem. Method of measurement: Serum meropenem levels will be analyzed using HPLC. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events associated with each administration method. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Assessment of the need for changes in the empirical antibiotic regimen or escalation of therapy. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Recurrence of fever within 72 hours after discontinuation of antibiotics. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information.;Response of inflammatory markers, including procalcitonin and CRP. Timepoint: Duration of hospitalization. Method of measurement: By reviewing patient file information. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMojtaba Shafiekhani
Shiraz University of Medical Sciences
Outcome results
None listed